The first and only Bruton’s tyrosine kinase (BTK) inhibitor approved for follicular lymphoma in the EU, now has the broadest label of any medicine in its class globally.
List view / Grid view
Following the CHMP’s recommendation of a follicular lymphoma combination treatment, if approved, BRUKINSA will be the first BTK inhibitor to be authorised for follicular lymphoma.
Medicines which represented significant progress in their therapeutic areas have been listed in the European Medicines Agency's Human Medicines Highlights 2022 report.
The FDA has accepted priority review of epcoritamab for adults with relapsed/refractory large B-cell lymphoma, which could be the first subcutaneous bispecific antibody for large B-cell lymphoma.
AstraZeneca announces plans to acquire TeneoTwo and its CD19/CD3 T-cell engager, TNB-486, in a deal worth up to $1.2bn.
Pfizer will acquire Trillium Therapeutics, an immuno-oncology company, potentially enhancing growth of cancer treatments from 2026.
In its March meeting the EMA’s human medicines committee recommended five medicines for approval and concluded its review of regdanvimab as a treatment for COVID-19.
Study shows most non-Hodgkin's lymphoma patients who achieve a remission lasting one year remain in remission for five years after receiving Novartis’ Kymriah™.
The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.
Investigators report 76 percent of trial participants had a complete response to axicabtagene ciloleucel (axi-cel), despite being resistant to other therapies.
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
NICE has given its positive opinion to lenalidomide in combination with rituximab as a 'chemotherapy-free' treatment for lymphoma.
25 April 2017 | By Niamh Marriott, Junior Editor
The Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions, separately recommending the approval of both Sandoz's (a Novartis division) biosimilar rituximab and biosimilar etanercept in Europe, to treat the same indications as their respective reference medicines.